Reportlinker Adds Pipeline and Commercial Insight: Neuropathic Pain - Pipeline Setbacks Prolong Pfizer's Supremacy
NEW YORK, April 28, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Introduction
At present, only six drugs are indicated for the treatment of neuropathic pain. In 2010, two significant events impacted the neuropathic pain market: the launch of Qutenza (8% capsaicin patch; NeurogesX/Astellas) in the US and EU; and the high-profile failure of ralfinamide (NW-1029; Newron) for the treatment of neuropathic low back pain.
Features and benefits
* Analysis of patient segmentation, epidemiology, current treatment approaches, and clinical unmet needs.* In depth analysis of historic (2005–09) and future (2010–19) seven major market prescription sales dynamics.* Discussion of R&D dynamics and pipeline trends in the neuropathic pain market.* Commercial and clinical assessment of key late-stage pipeline drugs with country-specific sales forecasts to 2019.* Insight provided by eight international key opinion leaders.
Highlights
The neuropathic pain market is expected to achieve peak sales of $4.1bn over the forecast period (2010–19) across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK).In addition to existing brands expanding into new regions, Datamonitor forecasts a total of eight pipeline candidates to enter the neuropathic pain market over the forecast period (2010–19) across the seven major markets. The broad label approval of Nucynta ER (extended-release tapentadol; Johnson & Johnson/Grunenthal) will drive market growth, while the launch of novel and topical agents will broaden treatment options.
Your key questions answered
* Who will be the winners and losers in the future neuropathic pain market?* What are the key unmet needs in the treatment of neuropathic pain?* What are the most promising drug candidates in development for the potential treatment of neuropathic pain?* Which neuropathic pain subtypes represent the most lucrative indications in which to seek regulatory approval?
Executive Summary
Strategic scoping and focus
Datamonitor insight into the neuropathic pain market
Related reports
OVERVIEW
Catalyst
Summary
1. PATIENT POTENTIAL
Key findings
Definition of neuropathic pain
Neuropathic pain can be defined by location, etiology, and severity
Diagnosis of neuropathic pain
Patient segmentation
Segmentation of neuropathic pain largely depends on the subtype
Segmentation of neuropathic pain differs depending on the symptoms
Epidemiology of neuropathic pain in the seven major markets
Neuropathic low back pain is the most prevalent of the neuropathic pain indications, affecting an estimated 29 million individuals across the seven major markets
Diabetic neuropathic pain affects an estimated 683,000 patients across the seven major markets
HIV-related neuropathic pain affects an estimated 332,000 people in the seven major markets
Post-herpetic neuralgia affects an estimated 307,000 people across the seven major markets
Other neuropathic pain subtypes
Current management of neuropathic pain
Treatments of neuropathic pain can involve pharmacological and non-pharmacological approaches
Consequences of inadequately treated neuropathic pain
Unmet need in neuropathic pain
The primary unmet need is improved efficacy in pain reduction and management
After efficacy, improved side-effect profile is the second most important unmet need
Reduction in pill burden will be increasingly important in the future with the use of combination therapies
Fewer drug-drug interactions will strengthen pipeline agents profile for use as a conjunctive therapy
Reduced time to onset of action is the least important unmet need
2. MARKET OVERVIEW
Market definition for this report
Seven major markets
Key events impacting the neuropathic pain market
Current and future market overview
US
Current and future market assessment
Japan
Current and future market assessment
Five major European markets
Current and future market assessment
France
Germany
Italy
Spain
UK
3. BRAND DYNAMICS
Overview of competitive landscape
Six treatments are currently marketed for neuropathic pain
Off-label prescribing
US formulary tier status for leading brands
Lyrica (pregabalin; Pfizer)
Drug overview
Drug profile
Product positioning
SWOT analysis
Brand forecast to 2019
Cymbalta (duloxetine; Eli Lilly/Shionogi)
Drug overview
Drug profile
Product positioning
SWOT analysis
Brand forecast to 2019
Lidoderm (5% lidocaine patch; Endo/Grunenthal/Teikoku)
Drug overview
Drug profile
Product positioning
SWOT analysis
Brand forecast to 2019
Qutenza (8% capsaicin patch; NeurogesX/Astellas)
Brand overview
Brand profile
Product positioning
SWOT analysis
Brand forecast to 2019
Other brands indicated for neuropathic pain
Neurontin (gabapentin; Pfizer)
Tegretol XR/CR (extended-release carbamazepine; Novartis)
4. PIPELINE OVERVIEW AND R&D DYNAMICS
Pipeline overview
Clinical pipeline
Classification of pipeline products
Glutamate receptor modulators
Ion channel modulators
GABA modulators
Others
Comparative forecasts
Datamonitor pipeline assessment summary
Definition of current comparator therapy
Pfizer's Lyrica is Datamonitor's comparator therapy for non-topical neuropathic pain treatments
Endo's Lidoderm is the topical comparator therapy
Pipeline candidates need to address efficacy, dosing regime, and side effects
5. R&D APPROACH
R&D approach differs depending on the geographic market
General neuropathic pain provides a broader customer base in the EU and Japan
US approval requires evidence in each neuropathic pain subtype
Clinical trial design in neuropathic pain
Choice of endpoint is the key clinical trial design factor in neuropathic pain
Clinical trial endpoints in neuropathic pain
A key challenge inherent in neuropathic pain clinical trials is recruitment of a homogenous, treatment-naïve patient population
6. PIPELINE ANALYSIS AND FORECASTS: GLUTAMATE MODULATORS
Pipeline summary
NP-1 (amitriptyline and ketamine; EpiCept)
Drug overview
Drug profile
Development overview
Clinical trial data
SWOT analysis
Datamonitor's drug assessment score card for NP-1
Clinical attractiveness
Commercial attractiveness
Satisfaction of unmet needs
Brand forecast to 2019
AVP-923 (dextromethorphan hydrobromide and quinidine sulfate; IriSys/Avanir)
Drug overview
Drug profile
Development overview
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for AVP-923
Clinical attractiveness
Commercial attractiveness
Satisfaction of unmet needs
Forecasts to 2019
Other glutamate modulators
NT11624 (dimiracetam; Brane Discovery/Neurotune)
7. PIPELINE ANALYSIS AND FORECASTS: ION CHANNEL MODULATORS
Pipeline summary
Ralfinamide (NW-1029; Newron)
Drug overview
Drug profile
Development overview
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for ralfinamide
Clinical attractiveness
Commercial attractiveness
Satisfaction of unmet needs
Brand forecast to 2019
Eladur (bupivacaine patch; Durect/King/Pfizer)
Drug overview
Drug profile
Development overview
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for Eladur
Clinical attractiveness
Commercial attractiveness
Satisfaction of unmet needs
Brand forecast to 2019
Other ion channel modulators
BIA 2-093 (eslicarbazepine acetate; Bial)
2PX (strontium chloride; SantoSolve AS)
8. PIPELINE ANALYSIS AND FORECASTS: GABA MODULATORS
Pipeline summary
DM-1796 (extended-release gabapentin; Depomed/Abbott)
Drug overview
Drug profile
Development overview
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for DM-1796
Clinical attractiveness
Commercial attractiveness
Satisfaction of unmet needs
Brand forecast to 2019
Horizant (gabapentin enacarbil; XenoPort/GlaxoSmithKline/Astellas)
Drug overview
Drug profile
Development overview
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for Horizant
Clinical attractiveness
Commercial attractiveness
Satisfaction of unmet needs
Brand forecast to 2019
9. PIPELINE ANALYSIS AND FORECASTS: OTHER
Pipeline summary
Nucynta ER (extended-release tapentadol HCl; Johnson & Johnson/Grunenthal)
Drug overview
Drug profile
Development overview
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for Nucynta ER
Clinical attractiveness
Commercial attractiveness
Satisfaction of unmet needs
Brand forecast to 2019
ARC-4558 (clonidine HCl; Arcion)
Drug overview
Drug profile
Development overview
Clinical trial data
SWOT analysis
Datamonitor drug assessment score card for ARC-4558
Clinical attractiveness
Commercial attractiveness
Satisfaction of unmet needs
Brand forecast to 2019
Other pipeline candidates
Sativex (tetrahydrocannabinol and cannabidiol; GW Pharma/Bayer)
ADL5859/PF4856880 (Adolor)
BIBLIOGRAPHY
Patient potential
Journals
Publications and online articles
Market overview
Publications and online articles
Brand dynamics
Journals
Publications and online articles
Pipeline overview and R&D dynamics
Journals
Publications and online articles
R&D approach
Journals
Pipeline analysis and forecasts: glutamate modulators
Publications and online articles
Pipeline analysis and forecasts: ion channel modulators
Journals
Publications and online articles
Pipeline analysis and forecasts: GABA modulators
Publications and online articles
Pipeline analysis and forecasts: other
Journals
Publications and online articles
Datamonitor reports
APPENDIX
Forecast assumptions
New product launches
Generic launches
Methodology
Datamonitor forecast methodology
Product forecasts
Definition of a standard unit
Derivation of sales forecasts and pricing trends
Exchange rates
Datamonitor drug assessment scorecard
Contributing experts
To order this report:
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article